Epizyme reported $231.83M in Debt for its third fiscal quarter of 2021.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Debt Change
Agios Pharmaceuticals AGIO:US $ 0.41M 0.59M
Amarin AMRN:US $ 0M 0M
Amgen AMGN:US $ 37579M 4797M
Avrobio Inc AVRO:US $ 0 0
Biogen BIIB:US $ 7271.1M 1.9M
Bluebird Bio BLUE:US $ 0M 0M
Cerulean Pharma CERU:US $ 0M 0M
Daiichi Sankyo 4568:JP Y 163647M 20092M
Eisai 4523:JP Y 89912M 2771M
Epizyme EPZM:US $ 231.84M 0.64M
Exelixis EXEL:US $ 0M 0M
Glaxosmithkline GSK:US $ 25605M 122M
GlaxoSmithKline GSK:LN 25605M 122M
Karyopharm Therapeutics KPTI:US $ 301.57M 195K
Macrogenics MGNX:US $ 0M 0M
Mirati Therapeutics MRTX:US $ 0M 0M
Novartis NOVN:VX SF 34243M 1526M
Novartis NVS:US $ 34243M 1526M
Regeneron Pharmaceuticals REGN:US $ 2698.6M 1M
Seattle Genetics SGEN:US $ 0M 0M
Spectrum Pharmaceuticals SPPI:US $ 0M 0M
Vertex Pharmaceuticals VRTX:US $ 513.26M 11.67M
Xencor XNCR:US $ 0M 0M